Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Jean‐Luc Van Laethem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0785-0580; OpenAlex author ID A5023909576, A5107940530. Sources: OpenAlex.

Their work

Papers
64 (first author 2, last author 23)
Trials
0
Grants
0
Labs led
2
Collaborators
201
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 3 papers · 2014: none · 2015: 4 papers · 2016: 6 papers · 2017: 4 papers · 2018: 2 papers · 2019: 6 papers · 2020: 1 paper · 2021: 7 papers · 2022: 4 papers · 2023: 10 papers · 2024: 8 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 64

  1. Evaluation of loco-regional recurrences using deformable image registration after isotoxic high dose stereotactic body radiotherapy in localised pancreatic can… Co-author DOI 10.1016/j.ctro.2025.101081↗
  2. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Last author DOI 10.1038/s41416-025-03274-0↗
  3. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  4. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  5. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Co-author DOI 10.1002/path.6212↗
  6. Anticipating pancreatic cancer diagnosis through early computerised tomography findings: An ongoing holy quest. Co-author DOI 10.1002/ueg2.12575↗
  7. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  8. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Last author DOI 10.1093/bjsopen/zrae134↗
  9. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Last author DOI 10.1101/2024.04.30.591890↗
  10. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging. Last author DOI 10.3390/biomedicines12030591↗
  11. Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better? Last author DOI 10.3390/cancers16132423↗
  12. Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.3390/diagnostics14070712↗
  13. Neoadjuvant chemotherapy associated with isotoxic high-dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduode… Last author DOI 10.1002/jso.27252↗
  14. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2023.102108↗
  15. Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience. Co-author DOI 10.1080/00015458.2021.1979173↗
  16. No evidence for the presence and control of tumor growth by cytoplasmic stress granules in pancreatic cancer Co-author DOI 10.1101/2023.11.13.566518↗
  17. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcin… Co-author DOI 10.1177/17588359231181500↗
  18. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… Last author DOI 10.1186/s12885-023-11327-x↗
  19. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  20. Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to B… Co-author DOI 10.3390/cancers15030768↗
  21. Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Co-author DOI 10.3390/cells12101414↗
  22. A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells13010003↗
  23. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  24. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Last author DOI 10.1016/j.esmoop.2022.100386↗
  25. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  26. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Eval… Co-author DOI 10.3390/cancers14235730↗
  27. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  28. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2021.01.042↗
  29. Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature. Last author DOI 10.1016/j.ejca.2021.07.042↗
  30. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Co-author DOI 10.1055/a-1324-2892↗
  31. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Last author DOI 10.1177/17588359211045860↗
  32. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Last author DOI 10.1245/s10434-020-09568-2↗
  33. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind. Last author DOI 10.3390/cancers13061231↗
  34. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Last author DOI 10.1177/1758835920936093↗
  35. Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer. Co-author DOI 10.1016/j.ejca.2018.10.010↗
  36. Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer? First author DOI 10.1016/s1470-2045(19)30107-x↗
  37. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗
  38. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Co-author DOI 10.1093/annonc/mdz181↗
  39. An update on treatment options for pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835919875568↗
  40. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
  41. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Last author DOI 10.1016/j.ejrad.2018.04.024↗
  42. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  43. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Co-author DOI 10.1007/s00018-017-2579-9↗
  44. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  45. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  46. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  47. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  48. Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation. Co-author DOI 10.1016/j.canep.2015.11.007↗
  49. Current standards and new innovative approaches for treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.12.026↗
  50. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗

Closest collaborators

The 25 strongest of 201 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christelle Bouchart · 19 shared papers, 2020–2026 · strength 3.59
  2. Julie Navez · 14 shared papers, 2020–2026 · strength 2.56
  3. Tatjana Arsenijevic · 13 shared papers, 2021–2026 · strength 2.19
  4. Maria Antonietta Bali · 8 shared papers, 2018–2024 · strength 1.53
  5. Jean‐Baptiste Bachet · 18 shared papers, 2011–2026 · strength 1.51
  6. Jean Closset · 11 shared papers, 2012–2024 · strength 1.37
  7. Rémy Nicolle · 9 shared papers, 2019–2026 · strength 1.32
  8. Pieter Demetter · 13 shared papers, 2012–2026 · strength 1.18
  9. Oier Azurmendi Senar · 6 shared papers, 2023–2026 · strength 1.14
  10. Nicky D’Haene · 6 shared papers, 2021–2026 · strength 1.05
  11. Raphaël Maréchal · 16 shared papers, 2011–2018 · strength 0.80
  12. Francesco Puleo · 9 shared papers, 2015–2022 · strength 0.80
  13. Kosta Stosic · 4 shared papers, 2023–2026 · strength 0.80
  14. Pascal R. Hammel · 12 shared papers, 2012–2025 · strength 0.77
  15. Karen Paula Geboes · 4 shared papers, 2022–2025 · strength 0.70
  16. Ilse Rooman · 4 shared papers, 2019–2026 · strength 0.65
  17. Jerome F. Cros · 7 shared papers, 2013–2023 · strength 0.65
  18. Thierry Conroy · 7 shared papers, 2012–2022 · strength 0.65
  19. Matthieu Hein · 4 shared papers, 2021–2026 · strength 0.64
  20. Magali Svrcek · 8 shared papers, 2012–2023 · strength 0.64
  21. Teresa Mercade Macarulla · 5 shared papers, 2017–2025 · strength 0.63
  22. Jaime Feliú · 4 shared papers, 2017–2025 · strength 0.58
  23. Léo Mas · 3 shared papers, 2023–2026 · strength 0.57
  24. Roberto Pazo-Cid · 3 shared papers, 2024–2025 · strength 0.52
  25. Aurélien Lambert · 4 shared papers, 2016–2025 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.